Sanders Morris Harris’s Cytokinetics CYTK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-21,505
Closed -$1.42M 121
2026
Q1
$1.42M Buy
+21,505
New +$1.37M 0.22% 88
2025
Q4
Sell
-21,505
Closed -$1.18M 100
2025
Q3
$1.18M Buy
+21,505
New +$886K 0.16% 99
2025
Q2
Sell
-21,505
Closed -$806K 199
2025
Q1
$806K Hold
21,505
0.12% 114
2024
Q4
$1.01M Hold
21,505
0.15% 103
2024
Q3
$1.14M Hold
21,505
0.19% 76
2024
Q2
$1.17M Hold
21,505
0.19% 72
2024
Q1
$1.51M Hold
21,505
0.28% 56
2023
Q4
$2.29M Hold
21,505
1.13% 20
2023
Q3
$603K Hold
21,505
0.12% 129
2023
Q2
$717K Buy
+21,505
New +$796K 0.16% 100
2023
Q1
Sell
-21,505
Closed -$985K 175
2022
Q4
$985K Buy
21,505
+750
+4% +$32.3K 0.37% 49
2022
Q3
$1.06M Sell
20,755
-1,000
-5% -$48.1K 0.26% 59
2022
Q2
$890K Hold
21,755
0.19% 81
2022
Q1
$801K Hold
21,755
0.16% 103
2021
Q4
$994K Hold
21,755
0.17% 89
2021
Q3
$841K Hold
21,755
0.15% 105
2021
Q2
$425K Hold
21,755
0.08% 197
2021
Q1
$508K Hold
21,755
0.11% 153
2020
Q4
$421K Sell
21,755
-2,800
-11% -$51.2K 0.1% 179
2020
Q3
$413K Buy
+24,555
New +$574K 0.11% 168
2020
Q2
Sell
-12,155
Closed -$145K 138
2020
Q1
$145K Buy
+12,155
New +$155K 0.14% 110

Other funds holding CYTK

Sanders Morris Harris's CYTK Position: Q2 2026 in Review

Sanders Morris Harris sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 21,505 shares — an estimated $1.42M sold.

Sanders Morris Harris first reported a position in CYTK in Q1 2020 and held it in 21 quarters. The position peaked at $2.29M in Q4 2023. 35 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Sanders Morris Harris reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Sanders Morris Harris sold 21,505 Cytokinetics shares in Q2 2026, an estimated $1.42M.
  • Sanders Morris Harris first reported a position in Cytokinetics in Q1 2020 and held it in 21 quarters.
  • Sanders Morris Harris's Cytokinetics position peaked at $2.29M in Q4 2023.
  • 35 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Sanders Morris Harris's 13F filing for Q2 2026, filed 7 Jul 2026.